



**Suppl. Figure 1:** Comparison of baseline- and follow up- cohort. Group I (n = 232-83): Randomized controlled trial; Group II (n = 83): Open label extension investigated at 24 month follow up. No significant differences between Group I and II.





Supplementary Figure 1

**Suppl. Figure 2:** Changes in ADAS-cog ( $\Delta$ ) from baseline to 24-months follow-up. (A) ADAS-cog and A $\beta$  1-42 ( $p = 0.0045$ ) and (B) ADAS-cog and total-Tau ( $p = 0.0063$ ).



Supplementary Figure 2

**Suppl. Figure 3:** Changes from baseline to 24-months follow-up. (A) in ADCS-ADL ( $\Delta$ ) and Cumulative treatment ( $p = 0.006$ ), (B) in CDR-SB ( $\Delta$ ) and Cumulative treatment ( $p = < 0.001$ ).



Supplementary Figure 3